Arş. Gör. HATİCE BÖLEK

1. Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma

Kuzu O. F., BÖLEK H., Sertesen Camoz E., Karakas H., Sekmek S., Sim S., et al.

BMC Cancer , cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)

2. Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study

Kopp R. M., Massari F., Grande E., Schieber T. J., ÜRÜN Y., Kopecký J., et al.

Cancer Immunology, Immunotherapy , cilt.74, sa.12, 2025 (SCI-Expanded, Scopus)

3. Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors-Data From the ARON-1 Study

Massari F., Rosellini M., Melichar B., Grande E., Bourlon M. T., Li H., et al.

JCO global oncology , cilt.11, 2025 (ESCI, Scopus)

4. Re: Hilin Yildirim, Katja K.H. Aben, Maarten J. Bijlsma, et al. A Nationwide Real-world Evaluation of Upfront Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma in the Immunotherapy Era. Eur Urol Oncol 2025;8:623-31

BÖLEK H.

European urology oncology , cilt.8, sa.5, ss.1436-1437, 2025 (SCI-Expanded, Scopus)

5. Enhancing outcomes in mCRPC: the impact of androgen receptor inhibitor sequencing before 177Lu-PSMA-617 therapy

YAZGAN S. C., Kayaş K., Arslan Ç., Kapar C., Öztekin Ş., Ceylan F., et al.

Oncologist , cilt.30, sa.9, 2025 (SCI-Expanded, Scopus)

6. Re: Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial

BÖLEK H., KUBİLAY TOLUNAY P.

ESMO Open , cilt.10, sa.9, 2025 (SCI-Expanded, Scopus)

7. Confirmation of Large Language Models in Head and Neck Cancer Staging

Kayaalp M., BÖLEK H., YAŞAR H. A.

Diagnostics , cilt.15, sa.18, 2025 (SCI-Expanded, Scopus)

8. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

Kalem A., Kus T., Sahin T. K., DİZDAR Ö., Efil S. C., Sendur M. A. N., et al.

Cancers , cilt.17, sa.17, 2025 (SCI-Expanded, Scopus)

9. Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study

Massari F., Mollica V., Kopp R. M., Grande E., Fiala O., Kanesvaran R., et al.

European Urology Focus , cilt.11, sa.5, ss.736-746, 2025 (SCI-Expanded, Scopus)

10. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

Kalem A., Kus T., Gokcek S., ÜNEK İ. T., Sahin T. K., DİZDAR Ö., et al.

Journal of Clinical Medicine , cilt.14, sa.16, 2025 (SCI-Expanded, Scopus)

11. The impact of smoking on nivolumab outcomes in renal cell carcinoma: Real-world data from the Turkish Oncology Group Kidney Cancer Consortium

Sertesen Camoz E., BÖLEK H., Kuzu O. F., Sim S., Karakaş H., Sekmek S., et al.

Oncologist , cilt.30, sa.7, 2025 (SCI-Expanded, Scopus)

12. Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium

BÖLEK H., Kuzu O. F., Sertesen Camoz E., Sim S., Sekmek S., Karakas H., et al.

Cancer Communications , cilt.45, sa.5, ss.572-576, 2025 (SCI-Expanded, Scopus)

13. Comparison of two alternative sequences with cabazitaxel and 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: A retrospective multicenter study (LuCaS)

BÖLEK H., Yazgan S. C., Ceylan F., Esteban-Villarrubia J., Arslan C., Kuş T., et al.

European Journal of Cancer , cilt.217, 2025 (SCI-Expanded, Scopus)

14. Impact of comorbidity on survival in cancer patients receiving immune checkpoint inhibitors

Yalciner M., YAZGAN S. C., EYLEMER MOCAN E., KARAOĞLAN B. B., BÖLEK H., YEKEDÜZ E., et al.

CLINICAL & TRANSLATIONAL ONCOLOGY , 2025 (SCI-Expanded, Scopus)

15. Evaluating the prognostic role of glucose-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors in first line: a study by the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

BÖLEK H., Kuzu O. F., Sertesen Camoz E., SİM YILDIRIM S., Sekmek S., Karakas H., et al.

CLINICAL & TRANSLATIONAL ONCOLOGY , 2025 (SCI-Expanded, Scopus)

16. Role of immune check point inhibitor rechallenge in metastatic renal cell carcinoma

BÖLEK H., Yazgan S. C., ÜRÜN Y., YEKEDÜZ E.

KIDNEY CANCER , cilt.9, ss.20-23, 2025 (ESCI, Scopus) Sürdürülebilir Kalkınma

17. Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium

Aykan M. B., BÖLEK H., YEKEDÜZ E., Sertesen E., Tural D., Karaçin C., et al.

Therapeutic Advances in Medical Oncology , cilt.17, 2025 (SCI-Expanded, Scopus)

18. The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617

YAZGAN S. C., Yekeduz E., ARAZ M., BÖLEK H., KÜÇÜK N. Ö., ÜRÜN Y.

Prostate , cilt.85, sa.1, ss.90-96, 2025 (SCI-Expanded, Scopus)

19. Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration-Sensitive Prostate Cancer

YAZGAN S. C., BÖLEK H., Coşkunpınar M., YEKEDÜZ E., ÜRÜN Y.

Prostate , 2025 (SCI-Expanded, Scopus)

20. Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study

Sekmek S., BÖLEK H., Kuzu O. F., Camoz E. S., Sim S., Karakaş H., et al.

Immunotherapy , cilt.17, sa.9, ss.649-655, 2025 (SCI-Expanded, Scopus)

21. Effect of HER2/CEP17 ratio on survival in metastatic HER2-positive gastric cancer, multicenter study

Sekmek S., Karahan I., Ucar G., Ceylan F., Bayram D., Seven I., et al.

Clinical and Translational Oncology , cilt.26, sa.8, ss.1878-1885, 2024 (SCI-Expanded, Scopus)

22. Perceptions and expectations: A study on prognostic perception and quality of life in patients with metastatic renal and bladder cancer.

Bolek H., Arslan C., Basaran M., Cicin I., Ozguroglu M., Tural D., et al.

JOURNAL OF CLINICAL ONCOLOGY , sa.16, 2024 (SCI-Expanded, Scopus)

23. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis.

BÖLEK H., Yekedüz E., ÜRÜN Y.

Cancer treatment reviews , cilt.122, ss.102667, 2024 (SCI-Expanded, Scopus)

24. Emerging Strategies in Adjuvant Immunotherapy: A Comparative Review of Bladder Cancer and Renal Cell Carcinoma Treatments

BALLI S., BÖLEK H., ÜRÜN Y.

CLINICAL MEDICINE INSIGHTS-ONCOLOGY , 2024 (SCI-Expanded, Scopus)

25. Adjuvant therapy for renal cell carcinoma: A systematic review of current landscape and future directions

BÖLEK H., ÜRÜN Y.

Critical Reviews in Oncology/Hematology , cilt.192, 2023 (SCI-Expanded, Scopus)

26. Cancer-associated thrombosis and drug-drug interactions of antithrombotic and antineoplastic agents